Modern views on the perfusion chemotherapy possibilities in the malignant tumors treatment

Currently, the complex treatment of malignant neoplasms of various localizations is used perfusion technology more commonly. We performed the analysis of literature on the use of perfusion chemotherapy in the treatment of tumors. The basic physical principles of delivering a chemotherapy drug (CP) to tumor tissues were considered, and it was noted that to ensure the effectiveness of this process, it is necessary to overcome high vascular resistance, high pressure of interstitial fluid and fibrous stroma around the tumor. It presented the factors contributing to the increase in CP in interstitial tissue, including ischemic vasodilation, low viscosity of injected fluids and bolus drug delivery. It is noted that when applying the method of intraarterial perfusion, the pressure of fluid flow increases, this causes the «leaching» of the intravascular protein in the interstitium, CP does not undergo reabsorption in the venous section, and the tumor is completely retained by the tissue. It is indicated that further study of the physicochemical principles of the application of this method will contribute to a significant increase in the survival rate of cancer patients in whom conservative treatment methods prove ineffective.

chemotherapy, malignant tumors, intraarterial perfusion, fluid mass transfer (MFT), oncotic pressure

1. Kemeny GA, Kanat NO. What is the potential role of hepatic arterial infusion chemo-therapy in the current armamentarium against colorectal cancer. J Gastrointest Oncol. 2012;3:130-138. DOI: 10.3978/j.issn.2078-6891.2011.025.

2. Burgmans MC, de Leede EM, Martini CH, Kapiteijn E, Vahrmeijer AL, van Erkel AR. Percutaneous isolated hepatic perfusion for the treatment of unresectable liver malignancies. Cardiovasc Interv Radiol. 2016;39:801-804. https://doi. org/10.1007/s00270-015-1276-z.

3. Lane RJ, Khin NY, Rogan CM, Magnussen JS, Ho-Shon KB, Pavlakis NF, Clarke SJ, Hugh TJ. The integration of pharmacology and pathophysiology into locoregional chemotherapy delivery via mass fluid transfer. J Control Release. 2018;28(292):18-28. DOI: 10.1016/j.jconrel.2018.10.019.

4. Rofstad EK, Galappathi K, Mathiesen BS. Tumor interstitial fluid pressure - a link between tumor hypoxia, microvascular density, and lymph node metastasis. Neoplasia. 2014;16:586-594. https://doi.org/10.1016/j.neo.2014.07.003.

5. Stapleton S, Milosevic M, Allen C, Zheng J, Dunne M, Yeung I, Jaffray DA. A mathematical model of the enhanced permeability and retention effect for liposome transport in solid tumors. PLoS One. 2013;8(12):e81157. DOI: 10.1371/ journal.pone.0081157.

6. Fisher DT, Muhitch JB, Kim M, Doyen KC, Bogner PN, Evans SS, Skitzki JJ. Intraoperative intravital microscopy permits the study of human tumour vessels. Nat Commun. 2016;7:10684. https://doi.org/10.1038/ncomms10684.

7. Van der Veldt AA, Lubberink M, Mathijssen RHJ, Loos WJ, Herder GJ, Greuter HN et al. Toward prediction of efficacy of chemotherapy: a proof of concept study in lung cancer patients using [(1)(1)C]docetaxel and positron emission tomography. Clin Cancer Res. 2013;19:4163-4173. https://doi. org/10.1158/1078-0432.CCR-12-3779.

8. Pingpank JE, Libutti SK, Chang R, Wood BJ, Neeman Z, Kam AW et al. Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. J Clin Oncol. 2005;23:3465-3474. https://doi.org/10.1200/ JCO.2005.00.927.

9. Vogl TJ, Zangos S, Scholtz JE, Schmitt F, Paetzold S, Trojan J et al. Chemosaturation with percutaneous hepatic perfusions of melphalan for hepatic metastases: experience from two European centers. Rofo. 2014;186:937-944. https://doi. org/10.1055/s-0034-1366081.

10. Lane RJ, Khin NY, Rogan CM, Magnussen J, Pavlakis N, Lane DM, Clarke S. Safety and feasibility of repeatable hepatic vascular isolation chemotherapy: a pilot study. Ann Surg Oncol. 2016;23:3699-3708. https://doi.org/10.1245/ s10434016-5198-z.

11. Devic S. Warburg effect - aconsequence or the cause of carcinogenesis? J Cancer. 2016;7:817-822. https://doi. org/10.7150/jca.14274.

12. Khin NY, Dijkstra ML, Huckson M, Phillips M, McMillan D, Itoh S et al. Hypertensive extracorporeal limb perfusion for critical limb ischemia. J Vasc Surg. 2013;58:1244-1253. https://doi.org/10.1016/j.jvs.2013.05.004.

13. Agarwala SS, Eggermont AM, O’Day S, Zager JS. Metastatic melanoma to the liver: a contemporary and comprehensive review of surgical, systemic, and regional therapeutic options. Cancer. 2014;120:781-789. https://doi.org/10.1002/cncr.

14. Woodcock TE, Woodcock TM. Revised Starling equation and the glycocalyx model of transvascular fluid exchange: an improved paradigm for prescribing intravenous fluid therapy. Br J Anaesth. 2012;108:384-394. https:// doi: 10.1093/bja/ aer515.

15. Taurin S, Nehoff H, van Aswegen T, Greish K. Tumor vasculature, EPR effect, and anticancer nanomedicine: connecting the dots. In: Y.H. Bae, R.J. Mrsny, K. Park (eds.), Cancer Target. Drug Deliv. - An Elus, Dream, Springer New York, New York, NY 2013:207-239. https://doi.org/10.1007/978-1-4614-7876-8-8.

16. Mimeault M, Hauke R, Batra SK. Stem cells: a revolution in therapeutics-recent advances in stem cell biology and their therapeutic applications in regenerative medicine and cancer therapies. Clin Pharmacol Ther. 2007;82:252-264. https://doi. org/10.1038/sj.clpt.6100301.

17. Fischer UM, Harting MT, Jimenez F, Monzon-Posadas WO, Xue H, Savitz SI et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev. 2009;18:683-692. https:// doi.org/10.1089/scd.2008.0253.

18. Pendharkar AV, Chua JY, Andres RH, Wang N, Gaeta X, Wang A et al. Biodistribution of neural stem cells after intravascular therapy for Hypoxic-ischemia. Stroke. 2010;41:2064-2070. https://doi.org/10.1161/STROKEAHA.109.575993.

19. Clavreul A, Pourbaghi-Masouleh M, Roger E, Lautram N, Montero-Menei CN, Menei P. Human mesenchymal stromal cells as cellular drug-delivery vectors for glioblastoma therapy: a good deal? J Exp Clin Cancer Res. 2017;36:135. https://doi. org/10.1186/s13046-017-0605-2.

20. Liu X, Yang X, Zhou G, Chen Y, Li C, Wang X. Gemcit-abine-based regional intraarterial infusion chemotherapy in patients with advanced pancreatic adenocarcinoma. Medicine (Baltimore). 2016;95:e3098. https://doi.org/10.1097/ MD.0000000000003098.

21. Fiorentini G, Tsetis D, Varveris C, Montagnani F, Kalogeraki A, Mambrini A et al. Induction intra-arterial chemotherapy (IAC) with epirubicin and mitoxantrone in locally advanced breast cancer. In: K.R. Aigner, F.O. Stephens (eds.), Induction Chemother, Springer Berlin Heidelberg, Berlin, Heidelberg. 2011:139-149. https://doi.org/10.1007/9783-642-18173-3-10.

22. Secomb TW, Konerding MA, West CA, Su M, Young AM, Mentzer SJ. Microangiectasias: structural regulators of lymphocyte transmigration. Proc Natl Acad Sci U.S.A. 2003;100:7231-7234. https://doi.org/10.1073/pnas. 1232173100.

23. Sleeman J, Schmid A, Thiele W Tumor lymphatics. Semin Cancer Biol. 2009;19:285-297. https://doi.org/10.1016/j. semcancer.2009.05.005.